Comparative Pharmacology
Head-to-head clinical analysis: DECADERM versus HC 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADERM versus HC 1.
DECADERM vs HC #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone acts as a glucocorticoid receptor agonist, binding to the cytoplasmic glucocorticoid receptor, leading to modulation of gene transcription, suppression of pro-inflammatory cytokines, and induction of anti-inflammatory proteins, thereby reducing inflammation and immune responses.
Unknown
DECADERM (dexamethasone) is typically administered as 0.75-9 mg/day orally in divided doses every 6-12 hours, depending on the condition. For acute indications, higher doses (up to 40 mg/day) may be given intravenously or intramuscularly.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
None Documented
None Documented
Terminal elimination half-life approximately 36–54 hours (mean 44 h); prolonged in hepatic impairment.
2–4 hours (terminal); prolonged in renal impairment.
Renal (primarily as inactive metabolites, <5% unchanged), fecal/biliary (<2%).
Renal: 90% as unchanged drug; fecal: 10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid